192
Participants
Start Date
April 29, 2019
Primary Completion Date
February 9, 2022
Study Completion Date
June 30, 2022
Bempegaldesleukin
Specified dose on specified days
Nivolumab
Specified dose on specified days
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
St Vincent's Hospital Sydney, Darlinghurst
GasthuisZusters Antwerpen, Wilrijk
Algemeen Ziekenhuis Klina, Brasschaat
Monash Health, Monash Medical Centre, Bentleigh East
CAIPO Centro para la atención integral del paciente oncológico, San Miguel de Tucumán
Tasman Health Care, Southport
Adelaide Cancer Centre, Kurralta Park
St John of God Murdoch Hospital, Nedlands
Ankara University Medical Faculty - PPDS, Ankara
AZ Groeninge, Kortrijk
Laura And Isaac Perlmutter Cancer Center, New York
Charité - Universitätsmedizin Berlin, Berlin
Centre François Baclesse, Caen
Istituto Nazionale Dei Tumori, Milan
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario HM Sanchinarro - CIOCC, Madrid
Hospital Universitario Ramon y Cajal, Pozuelo de Alarcón
Southeastern Regional Medical Center - CTCA - PPDS, Newnan
Winship Cancer Institute, Emory University, Atlanta
Rambam Medical Center - PPDS, Haifa
Centro Di Riferimento Oncologico, Aviano
Izmir Medicalpark Hospital, Izmir
Hospital Universitario Virgen del Rocio - PPDS, Seville
University General Hospital of Larissa, Larissa
Inonu University Faculty of Medicine Turgut Ozal Medical Center, Malatya
Meir Medical Center, Kfar Saba
Edog Ico - Ppds, Saint-Herblain
Fundacion Instituto Valenciano de Oncologia, Valencia
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS, Meldola
Tel Aviv Sourasky Medical Center PPDS, Tel Aviv
Sheba Medical Center - PPDS, Ramat Gan
Euromedica - PPDS, Thessaloniki
Phylasis Clinicas Research S. de R.L. de C.V., Cuautitlán Izcalli
Investigator Site - Peoria, Peoria
Shamir Medical Center Assaf Harofeh, Ẕerifin
Centre Jean Bernard Clinique Victor Hugo, Le Mans
Studienpraxis Urologie, Nürtingen
Hôpital Européen Georges Pompidou, Paris
MD Anderson Cancer Center, Houston
Rocky Mountain Cancer Centers, Aurora
Hôpital Privé TOULON/HYERES Sainte Marguerite, Hyères
Innovative Clinical Research Institute, LLC, Whittier
Kliniken Nordoberpfalz AG, Weiden
San Francisco VA Medical Center - NAVREF - PPDS, San Francisco
Institut Gustave Roussy, Villejuif
Regional Clinical Oncology Hospital, Yaroslavl
Railway Clinical Hospital JSC RZhD, Saint Petersburg
PMI Euromedservice, Pushkin
Federal State Institution Medical Radiology Research Center, Obninsk
Clinical Oncology Dispensary, Omsk
Centro de Investigación Clínica - Clínica Viedma, Viedma
Instituto de Oncologia de Rosario, Rosario
Hospital Alemán, Buenos Aires
Instituto Médico Especializado Alexander Fleming, Buenos Aires
Centro Médico Privado CEMAIC, Córdoba
Sanatorio Privado Duarte Quirós, de Clínica Colombo S.A., Córdoba
University Health Network, Toronto
Helsingin Yliopistollinen Keskussairaala - PPDS, Helsinki
Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden
Alexandra Hospital, Athens
Medical Center of Athens, Marousi
Health Pharma Professional Research S.A de C.V., Mexico City
Centro Hospitalar E Universitário de Coimbra EPE, Coimbra
Hospital General Universitario de Elche, Elche
Hospital de La Santa Creu i Sant Pau, Barcelona
Hospital del Mar, Barcelona
Royal Marsden Hospital - Surrey, Sutton
Leicester Royal Infirmary, Leicester
Barts Health NHS Trust, London
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Nektar Therapeutics
INDUSTRY